艾塞那肽对2型糖尿病患者血管内皮功能及心血管疾病危险因素的影响

发布时间：2018-06-29 13:35

本文选题：艾塞那肽 + 2型糖尿病　；参考：《广西医科大学》2017年硕士论文

【摘要】：目的:研究艾塞那肽对2型糖尿病患者血管内皮功能及心血管疾病相关危险因素的影响。方法:将初发的2型糖尿病患者随机分为两组,一组为对照组,给予指导饮食,调整饮食结构,合理运动;一组艾塞那肽治疗组,给予艾塞那肽皮下注射治疗,前4周给予艾塞那肽5ug/次,早晚餐前各一次,后8周10ug/次,早晚餐前各一次,共12周,观察治疗前后血管内皮功能相关指标,如可溶性细胞间粘附分子(s ICAM-1)、可溶性血管细胞间粘附分子(s VCAM-1)及单核细胞趋化因子(MCP-1),肱动脉血流介导的血管舒张功能(FMD);同时监测治疗前后心血管疾病相关的代谢性指标,如空腹血糖、空腹C肽、糖化血红蛋白(Hb Ac1),总胆固醇、甘油三酯、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇,体重、体质指数、腹围。结果:对照组治疗前后s ICAM-1、s VCAM-1、MCP-1、FMD水平差异无统计学意义(P0.05);艾塞那肽组治疗12周后较治疗前s ICAM-1、s VCAM-1、MCP-1水平下降,FMD升高,且差异有统计学意义(P0.05);治疗12周后艾塞那肽组较对照组s ICAM-1、s VCAM-1、MCP-1水平下降(P0.05),FMD升高(P0.05)。对照组治疗治疗前后空腹血糖、糖化血红蛋白(Hb Ac1)、总胆固醇、甘油三酯、低密度脂蛋白胆固醇、体重、体质指数、腹围、空腹C肽水平差异无统计学意义(P0.05);艾塞那肽组治疗12周后较治疗前比较空腹血糖、糖化血红蛋白(Hb Ac1)、总胆固醇、甘油三酯、低密度脂蛋白胆固醇、体重、体质指数、腹围水平下降,空腹C肽水平上升,且差异有统计学意义(P0.05);两组高密度脂蛋白胆固醇升高,但差异均无统计学意义(P0.05)。结论:艾塞那肽能改善心血管疾病相关的代谢异常,对血管内皮功能有一定保护作用,可能一定程度的预防和减慢心血管事件的发生及发展。
[Abstract]:Aim: to study the effects of Isenapeptide on vascular endothelial function and cardiovascular risk factors in patients with type 2 diabetes mellitus. Methods: the patients with type 2 diabetes mellitus were randomly divided into two groups: the control group, the control group and the control group. In the first 4 weeks, Isenapeptide 5ug/ was given once before morning and evening, once before meal, 8 weeks after meal, and once before morning and evening for 12 weeks. The relative indexes of vascular endothelial function were observed before and after treatment. Such as soluble intercellular adhesion molecule (sICAM-1), soluble vascular intercellular adhesion molecule (sVCAM-1), monocyte chemokine (MCP-1), brachial artery flow-mediated vasodilation (FMD), metabolic indexes related to cardiovascular disease before and after treatment. Such as fasting blood glucose, fasting C-peptide, glycosylated hemoglobin (HB Ac1), total cholesterol, triglyceride, low density lipoprotein cholesterol, high density lipoprotein cholesterol, body mass, body mass index, abdominal circumference. Results: there was no significant difference in the level of FMD between control group and control group before and after treatment (P0.05), and the level of MCP-1 decreased and FMD increased after 12 weeks of treatment in Eisenapeptide group. And the difference was statistically significant (P0.05); after 12 weeks of treatment, the level of MCP-1 in the Eisenapeptide group was significantly lower than that in the control group (P0.05). In the control group, fasting blood glucose, HB Ac1, total cholesterol, triglyceride, low density lipoprotein cholesterol, body weight, body mass index, abdominal circumference were measured before and after treatment. There was no significant difference in fasting C-peptide level (P0.05), fasting blood glucose, glycosylated hemoglobin (HB Ac1), total cholesterol, triglyceride, low density lipoprotein cholesterol, body weight, body mass index (BMI) were compared after 12 weeks of treatment in Eisenapeptide group. Abdominal circumference level decreased, fasting C-peptide level increased, and the difference was statistically significant (P0.05); two groups of high density lipoprotein cholesterol increased, but the difference was not statistically significant (P0.05). Conclusion: Isenapeptide can improve the metabolic abnormalities associated with cardiovascular disease and protect vascular endothelial function. It may prevent and slow down the occurrence and development of cardiovascular events to some extent.
【学位授予单位】：广西医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R587.1

【参考文献】